**Analysis:**

The earnings call for Amgen Inc. reveals a strong performance in the second quarter of 2024, with revenues growing 20% year-over-year to $8.4 billion. The company's innovative medicines, particularly in the rare disease and oncology sectors, are driving significant growth. Key highlights include the approval of IMDELLTRA for small cell lung cancer and the positive top-line results for UPLIZNA in IgG4-related disease. The company's strategic focus on obesity, with the MariTide Phase II study expected to deliver data later this year, also shows promise. Management's tone is optimistic, with clear plans for future growth and expansion.

**Conclusion:**

Given the strong performance, innovative pipeline, and positive outlook, I predict a **positive impact** on the stock price over the next 1-2 weeks. Investors are likely to be encouraged by the company's continued success in delivering innovative medicines and its strategic focus on growth areas. The stock could see a rally as investors anticipate further positive developments and earnings growth.

**Rating:** 1